



Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
(CIN:U24232GJ1996PLC029894)



Date: 14th August, 2021

To,

<p>The General Manager, Corporate relations department, BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai- 400 001</p> <p>Scrip Code: 543321 Though: BSE Corporate Compliance & listing Centre</p>	<p>The Manager, Listing Department, National Stock Exchange of India Limited Exchange Plaza, C- 1, Block-G, Bandra-Kurla, Complex Bandara (E), Mumbai 400 051</p> <p>Scrip Symbol: TATVA Through: NEAPS</p>
---	---

Subject: Outcome of Board Meeting dated 14th August, 2021 as required under Regulation 30 of the SEBI (listing Obligations and Disclosure Requirements) Regulations 2015.

Dear sir/Madam,

With reference to our previous communication through letter dated 06th August 2021, regarding intimation of Meeting of the Board of Directors and business to be transacted thereat etc., and in continuous to the same, this is to inform you that the Meeting of Board of Directors commenced at 11.00 a.m today *inter alia* has considered & approved the following business:

1. Copy of the **Limited Review Report** of the Statutory Auditors of the Company, **M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W)**, on the Un-audited Consolidated Financial Results;
2. Copy of **the Un-audited Consolidated Financial Results** of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22;

Factory and Registered Office: Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District:Bharuch, Gujarat, India.
SEZ Unit: Plot No. Z/103/F/1 and Plot No. Z/103/F/2, SEZ Area Part-2 , Dahej - 392 130, District: Bharuch, Gujarat, India.
DSIR Approved R & D Centre: Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.
Telephone No. +91 75748 48533 / 34 **Fax :** +91 265 263 8533
E-mail: chintan@tatvachintan.com **Website:** www.tatvachintan.com



Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
(CIN:U24232GJ1996PLC029894)



3. Copy of the **Limited Review Report** of the Statutory Auditors of the Company, **M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W)**, on the Un-audited Standalone Financial Results;
4. Copy of the **Un-audited Standalone Financial Results** of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22;
5. Appointment of **M/s. TNT & Associates, Company Secretaries**, as Secretarial Auditors of the Company to conduct Secretarial Audit for the Financial Year 2021-22;
6. Appointment of **M/s. RSM Astute Consultech Private Limited** as Internal Auditors of the Company to conduct Internal Audit for the Financial Year 2021-22.

The Board Meeting commenced at 11.00 a.m (IST) and concluded at 05:35 p.m (IST).

You are therefore requested to take note of the same.

Thanking you,

Yours faithfully,

For Tatva Chintan Pharma Chem Limited



Apurva Dubey

Company Secretary and Compliance Officer

Membership No.: A-41130

Encl. : As stated above.

Factory and Registered Office: Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District:Bharuch, Gujarat, India.

SEZ Unit: Plot No. Z/103/F/1 and Plot No. Z/103/F/2, SEZ Area Part-2 , Dahej - 392 130, District: Bharuch, Gujarat, India.

DSIR Approved R & D Centre: Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

Telephone No. +91 75748 48533 / 34 **Fax :** +91 265 263 8533

E-mail: chintan@tatvachintan.com **Website:** www.tatvachintan.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF TATVA CHINTAN PHARMA CHEM LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Tatva Chintan Pharma Chem Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2021 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended for the purpose of filing it with the Bombay Stock Exchange and the National Stock Exchange of India Limited.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
5. The Statement includes the results of the following entities:
 - a) Tatva Chintan Pharma Chem Limited – the Parent Company
 - b) Tatva Chintan USA Inc. – the Subsidiary Company
 - c) Tatva Chintan Europe B.V – the Subsidiary Company
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. One subsidiary included in the consolidated unaudited financial results, whose interim financial statements reflect total income (before consolidation adjustments) of Rs. 164.76 Million, total net profit after tax (before consolidation adjustments) of Rs. 2.31 Million and total comprehensive income (before consolidation adjustments) of Rs. 2.31 Million for the quarter ended 30th June, 2021 which is located outside India and its interim financial statements have been prepared in accordance with accounting policies generally accepted in that country ("local GAAP") which have been reviewed by other auditor under generally accepted auditing standards applicable in that country. The Holding Company's management has converted the interim financial statements of the subsidiary from the local GAAP to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the reports of the other auditor and conversion adjustments made by the management of the Holding Company and reviewed by us.

The unaudited consolidated financial results includes the financial results of one subsidiary which has not been subjected to limited review by their auditors and have been presented based on the financial information certified to us by the Company's management whose unaudited financial information reflects total income (before consolidation adjustments) of Rs. 129.76 million, total net profit after tax (before consolidation adjustments) of Rs. 3.97 Million and total comprehensive income (before consolidation adjustments) of Rs. 3.97 Million for the quarter ended 30th June, 2021 as considered in the Statement. Our conclusion on the unaudited consolidated financial results in so far as it relates to the amounts and disclosures in respect of this subsidiary is based solely on such unaudited financial information and explanation given to us by the Company's Management, this financial information is not material to the Group.

Our conclusion on the Statement is not modified in respect of this matter.


8. The Statement includes results for the quarter ended 31st March, 2021 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to third quarter of the financial year which were subjected to special purpose audit by us.

The Statement also includes results for the quarter ended 30th June, 2020 has been presented based on information compiled by the management after making necessary adjustments to give a true and fair view of the results in accordance with Ind AS, and have not been subjected to limited review by us.

Our conclusion on the Statement is not modified in respect of this matter.

9. Our report is intended solely for use of the management for its onward submission to the BSE Limited and National Stock Exchange of India Limited in connection with the listing of equity shares of the Company as mentioned in Para 1 above. As a result, the Statement may not be suitable for another purpose. Our report should not be used, referred to or distributed for any other purpose except with our prior consent in writing.

For NDJ & Co.,
Chartered Accountants
Firm's Registration Number: 136345W


CA Shrish Shah
Partner

Membership No. 035742
UDIN No: - 21035742AAAAER4490



Date: 14th August 2021
Place: Surat



Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
CIN: U24232GJ1996PLC029894

Registered Office: Plot No. 502 / 17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Web Site : www.tatvachintan.com, E-mail : chintan@tatvachintan.com , Tel. No.: +91 75748 48533

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

(Rupees in millions, except per share data)

Sl. No.	Particulars	Quarter ended			Year ended
		30 June 2021 (Unaudited)	31 March 2021 (Unaudited)	30 June 2020 (Unaudited)	31 March 2021 (Audited)
1	Revenue from operations	1,068.32	1,086.67	515.32	3,003.59
2	Other income	29.68	25.91	1.68	59.33
3	Total income (1+2)	1,098.00	1,112.58	517.00	3,062.92
4	Expenses				
	a) Cost of materials consumed	516.60	480.00	276.23	1,509.12
	b) Purchases of stock-in-trade	12.03	11.59	2.37	25.37
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	3.43	82.43	(16.07)	(40.57)
	d) Employee benefits expenses	71.26	68.94	47.59	241.31
	e) Finance costs	26.42	10.45	4.95	42.07
	f) Depreciation and amortisation expense	18.98	17.75	16.82	67.32
	g) Other expenses	206.67	199.03	101.75	611.34
	Total expenses	855.39	870.19	433.64	2,455.96
5	Profit / (loss) before exceptional items and tax (3-4)	242.61	242.39	83.36	606.96
6	Exceptional items	-	-	-	-
7	Profit / (loss) before tax (5-6)	242.61	242.39	83.36	606.96
8	Tax expenses				
	Current tax	42.62	43.14	20.02	108.11
	Deferred tax	(31.47)	(11.94)	(3.76)	(23.77)
	Total tax expenses	11.15	31.20	16.26	84.34
9	Profit / (loss) for the period (7-8)	231.46	211.19	67.10	522.62
10	Other comprehensive income				
	Items that will not be reclassified to profit or loss	(1.49)	1.62	0.14	2.07
	Income tax relating to items that will not be reclassified to profit or loss	0.41	(0.47)	(0.04)	(0.60)
	Other comprehensive income for the period, net of tax	(1.08)	1.15	0.10	1.47
11	Total comprehensive income for the period (9+10)	230.38	212.34	67.20	524.09
12	Profit / (loss) for the period attributable to:				
	- Owners of the Company	231.46	211.19	67.10	522.62
	- Non controlling interests	-	-	-	-
		231.46	211.19	67.10	522.62
13	Other comprehensive income for the period attributable to:				
	- Owners of the Company	(1.08)	1.15	0.10	1.47
	- Non controlling interests	-	-	-	-
		(1.08)	1.15	0.10	1.47
14	Total comprehensive income for the period attributable to:				
	- Owners of the Company	230.38	212.34	67.20	524.09
	- Non controlling interests	-	-	-	-
		230.38	212.34	67.20	524.09
15	Earnings per share (Face value of Rs 10/- each) (not annualised)				
	- Basic	11.52	10.51	3.34	26.02
	- Diluted	11.52	10.51	3.34	26.02
16	Paid up equity share capital (Face value of Rs 10/- each)	200.88	200.88	80.35	200.88
17	Other equity excluding revaluation reserve				1,458.76

See accompanying notes to the financial results.



Chintan Patel





Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
CIN: U24232GJ1996PLC029894

Registered Office: Plot No. 502 / 17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Web Site : www.tatvachintan.com, E-mail : chintan@tatvachintan.com , Tel. No.: +91 75748 48533

NOTES TO STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2021 ("Unaudited Consolidated Financial Results") of Tatva Chintan Pharma Chem Limited (the "Holding Company" or the "Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14 August 2021 and have been subject to a limited review by the Statutory Auditors of the Company.
- 2 The Unaudited Consolidated Financial Results of the Group for quarter ended 31 March 2021 are the balancing figures between audited figures in respect of full financial year upto 31 March 2021 and the special purpose audited figures upto the third quarter ended 31 December 2020.
- 3 The Unaudited Consolidated Financial Results of the Group for the quarter ended 30 June 2020 as reported in the accompanying statement have been approved by the Board of Directors on 14 August 2021 and has been presented based on information compiled by the management after making necessary adjustments to give a true and fair view of the results in accordance with Ind AS, but have not been subjected to limited review by the statutory auditors.
- 4 The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.
- 5 The full impact of COVID-19 still remains uncertain and could be different from the estimates considered while preparing these Unaudited Consolidated Financial Results. The Group will continue to closely monitor any material changes to future economic conditions.
- 6 Subsequent to quarter ended 30 June 2021, the Company has completed Initial Public Offer (IPO) of 4,616,804 Equity Shares of the face value of Rs. 10/- each at an issue price of Rs. 1083/- per equity share (including a premium of Rs. 1,073 per equity share) aggregating to Rs. 5,000.00 Million. The offer comprises of a fresh issue of 2,077,562 equity shares aggregating to Rs. 2,250.00 Million and an offer for sale of 2,539,242 equity shares aggregating to Rs. 2,750.00 Million. The equity shares of the Company were listed on 29 July 2021 on BSE Limited (BSE) and National Stock Exchange of India Limited (NSE).
- 7 The Company has received IPO proceeds on 30 July 2021 i.e. after quarter ended 30 June 2021, Thus, statement of utilization of IPO proceeds pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 shall be filed from next quarter.
- 8 The basic and diluted earning per share for the quarter ended 30 June 2021 has been presented based on Pre-IPO paid up equity share capital. Further, the basic and diluted earning per share for the comparative period ended 30 June 2020 has been presented to reflect the adjustments for issue of bonus shares as approved by Board on 03 March 2021, in accordance with Ind AS 33 - Earnings per share.
- 9 The Group is in the business of manufacturing of specialty chemicals, accordingly it has only one reportable segment.
- 10 The above Unaudited Consolidated Financials Results of the Group are available on Company's website www.tatvachintan.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.
- 11 Figures for the previous periods/year are re-classified/re-arranged/re-grouped, wherever necessary.

For and on behalf of the Board of Directors

Tatva Chintan Pharma Chem Limited
Chairman & Managing Director

Place : Vadodara

Date : 14 August 2021




**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS
TO THE BOARD OF DIRECTORS OF TATVA CHINTAN PHARMA CHEM LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Tatva Chintan Pharma Chem Limited ("the Company") for the quarter ended 30th June 2021 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended for the purpose of filing it with the Bombay Stock Exchange and the National Stock Exchange of India Limited.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement includes results for the quarter ended 31st March, 2021 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to third quarter of the financial year which were subjected to special purpose audit by us.
The Statement also includes results for the quarter ended 30th June, 2020 presented based on information compiled by the management after making necessary adjustments to give a true and fair view of the results in accordance with Ind AS, and have not been subjected to limited review by us.
Our conclusion on the Statement is not modified in respect of this matter.
6. Our report is intended solely for use of the management for its onward submission to the BSE Limited and National Stock Exchange of India Limited in connection with the listing of equity shares of the Company as mentioned in Para 1 above. As a result, the Statement may not be suitable for another purpose. Our report should not be used, referred to or distributed for any other purpose except with our prior consent in writing.

For NDJ & Co.,
Chartered Accountants
Firm's Registration Number: 136345W

CA Shrish Shah
Partner
Membership No. 035742
UDIN No:- 21035742AAAAEQ3025



Date: 14th August 2021
Place: Surat



Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
CIN: U24232GJ1996PLC029894

Registered Office: Plot No. 502 / 17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Web Site : www.tatvachintan.com, E-mail : chintan@tatvachintan.com , Tel. No.: +91 75748 48533

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

(Rupees in millions, except per share data)

Sl. No.	Particulars	Quarter ended			Year ended
		30 June 2021 (Unaudited)	31 March 2021 (Unaudited)	30 June 2020 (Unaudited)	31 March 2021 (Audited)
1	Revenue from operations	1,076.50	1,044.97	520.73	2,911.88
2	Other income	27.71	20.10	0.24	50.98
3	Total income (1+2)	1,104.21	1,065.07	520.97	2,962.86
4	Expenses				
	a) Cost of materials consumed	516.60	480.00	276.23	1,509.12
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	30.81	75.53	(8.06)	(51.97)
	d) Employee benefits expenses	71.26	68.95	47.59	241.31
	e) Finance costs	26.42	10.45	4.95	42.07
	f) Depreciation and amortisation expense	18.98	17.75	16.82	67.30
	g) Other expenses	190.35	180.13	86.10	561.55
	Total expenses	854.42	832.81	423.63	2,369.38
5	Profit / (loss) before exceptional items and tax (3-4)	249.79	232.26	97.34	593.48
6	Exceptional items	-	-	-	-
7	Profit / (loss) before tax (5-6)	249.79	232.26	97.34	593.48
8	Tax expenses				
	Current tax	41.70	40.67	20.02	103.66
	Deferred tax	(31.47)	(11.94)	(3.76)	(23.77)
	Total tax expenses	10.23	28.73	16.26	79.89
9	Profit / (loss) for the period (7-8)	239.56	203.53	81.08	513.59
10	Other comprehensive income				
	Items that will not be reclassified to profit or loss	(1.49)	1.62	0.14	2.07
	Income tax relating to items that will not be reclassified to profit or loss	0.41	(0.47)	(0.04)	(0.60)
	Other comprehensive income for the period, net of tax	(1.08)	1.15	0.10	1.47
11	Total comprehensive income for the period (9+10)	238.48	204.68	81.18	515.06
12	Earnings per share (Face value of Rs 10/- each) (not annualised)				
	- Basic	11.93	10.13	4.04	25.57
	- Diluted	11.93	10.13	4.04	25.57
13	Paid - up equity share capital (Face value of Rs 10/- each)	200.88	200.88	80.35	200.88
14	Other equity excluding revaluation reserve				1,418.48

See accompanying notes to the financial results.



Chintan Shah



Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
CIN: U24232GJ1996PLC029894

Registered Office: Plot No. 502 / 17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Web Site : www.tatvachintan.com, E-mail : chintan@tatvachintan.com , Tel. No.: +91 75748 48533

NOTES TO STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2021 ("Unaudited Standalone Financial Results") of Tatva Chintan Pharma Chem Limited ("the "Company") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14 August 2021 and have been subject to a limited review by the Statutory Auditors of the Company.
- 2 The Unaudited Standalone Financial Results of the Company for quarter ended 31 March 2021 are the balancing figures between audited figures in respect of full financial year upto 31 March 2021 and the special purpose audited figures upto the third quarter ended 31 December 2020.
- 3 The Unaudited Standalone Financial Results of the Company for the quarter ended 30 June 2020 as reported in the accompanying statement have been approved by the Board of Directors on 14 August 2021 and has been presented based on information compiled by the management after making necessary adjustments to give a true and fair view of the results in accordance with Ind AS, but have not been subjected to limited review by the statutory auditors.
- 4 The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.
- 5 The full impact of COVID-19 still remains uncertain and could be different from the estimates considered while preparing these Unaudited Standalone Financial Results. The Company will continue to closely monitor any material changes to future economic conditions.
- 6 Subsequent to quarter ended 30 June 2021, the Company has completed Initial Public Offer (IPO) of 4,616,804 Equity Shares of the face value of Rs. 10/- each at an issue price of Rs. 1083/- per equity share (including a premium of Rs. 1,073 per equity share) aggregating to Rs. 5,000.00 Million. The offer comprises of a fresh issue of 2,077,562 equity shares aggregating to Rs. 2,250.00 Million and an offer for sale of 2,539,242 equity shares aggregating to Rs. 2,750.00 Million. The equity shares of the Company were listed on 29 July 2021 on BSE Limited (BSE) and National Stock Exchange of India Limited (NSE).
- 7 The Company has received IPO proceeds on 30 July 2021 i.e. after quarter ended 30 June 2021, Thus, statement of utilization of IPO proceeds pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 shall be filed from next quarter.
- 8 The basic and diluted earning per share for the quarter ended 30 June 2021 has been presented based on Pre-IPO paid up equity share capital. Further, the basic and diluted earning per share for the comparative period ended 30 June 2020 has been presented to reflect the adjustments for issue of bonus shares as approved by Board on 03 March 2021, in accordance with Ind AS 33 - Earnings per share.
- 9 The Company is in the business of manufacturing of specialty chemicals, accordingly it has only one reportable segment.
- 10 The above Unaudited Standalone Financials Results of the Company are available on Company's website www.tatvachintan.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.
- 11 Figures for the previous periods/year are re-classified/re-arranged/re-grouped, wherever necessary.

For and on behalf of the Board of Directors

Tatva Chintan Pharma Chem Limited
Chairman & Managing Director

Place : Vadodara

Date : 14 August 2021





Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
(CIN:U24232GJ1996PLC029894)



Disclosure of information pursuant to Regulation 30 of SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015.

Appointment of Secretarial Auditors:

Sr. No	Particulars	Details
1.	Name of Auditor	M/s. TNT & Associates, Company Secretaries
2.	Reason for Change Viz., appointment, resignation, removal, death or otherwise;	Appointment.
3.	Date of Appointment/cessation (as applicable) & terms of appointment	14th August, 2021 M/s. TNT & Associates, Company, Practicing Company Secretaries firm is appointed as Secretarial Auditor of the Company. Terms of appointment: To Conduct Secretarial Audit for Financial Year 2021-22.
4.	Brief profile (in case of appointment)	M/s. TNT & Associates (Peer Review Firm) Established as a partnership firm. This firm is an integrated Corporate, Secretarial & Legal Services Firm, offering a One-Stop solution for all Corporate compliances and Legal Requirements. The firm offers various Secretarial, legal and compliance services to ensure the regulatory compliances and make ease of burden of compliance to the entrepreneur. The firm also offers advisory services on corporate restructuring, subsidy matters, insolvency matters and other regulatory compliance services.
5.	Disclosure of relationships between directors (in case of appointment of a director).	None



Factory and Registered Office: Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District:Bharuch, Gujarat, India.
SEZ Unit: Plot No. Z/103/F/1 and Plot No. Z/103/F/2, SEZ Area Part-2 , Dahej - 392 130, District: Bharuch, Gujarat, India.
DSIR Approved R & D Centre: Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.
Telephone No. +91 75748 48533 / 34 **Fax :** +91 265 263 8533
E-mail: chintan@tatvachintan.com **Website:** www.tatvachintan.com



Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
(CIN:U24232GJ1996PLC029894)



Disclosure of information pursuant to Regulation 30 of SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015.

Appointment of Internal Auditors:

Sr. No	Particular	Details
01	Name of Auditor	M/s. RSM Astute Consultech Private Limited
02	Reason for Change Viz., appointment. Resignation, removal, death or otherwise;	Appointment.
03	Date of Appointment/cessation (as applicable) & terms of appointment	14th August, 2021 M/s. RSM Astute Consultant Private Limited is appointed as Internal Auditor of the Company. Terms of appointment: To Conduct Internal Audit for Financial Year 2021-22.
04	Brief profile (in case of appointment)	RSM Astute Consultech Private Limited with its affiliate viz. Suresh Surana & Associates LLP (together referred as 'RSM India'), consistently ranks amongst India's top 6 accounting and consulting groups (International Accounting Bulletin, September 2019). The Company having Multi-disciplinary team of professionals comprising of Chartered Accountants, MBAs, Company Secretaries, CISA / ISA professionals, Cost Accountants, Law Graduates and Engineers.
05	Disclosure of relationships between directors (in case of appointment of a director).	None



text here

Factory and Registered Office: Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District:Bharuch, Gujarat, India.
SEZ Unit: Plot No. Z/103/F/1 and Plot No. Z/103/F/2, SEZ Area Part-2 , Dahej - 392 130, District: Bharuch, Gujarat, India.
DSIR Approved R & D Centre: Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.
Telephone No. +91 75748 48533 / 34 **Fax :** +91 265 263 8533
E-mail: chintan@tatvachintan.com **Website:** www.tatvachintan.com